Compare KLXE & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KLXE | INMB |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.1M | 57.9M |
| IPO Year | 2018 | 2018 |
| Metric | KLXE | INMB |
|---|---|---|
| Price | $1.63 | $2.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.40 |
| AVG Volume (30 Days) | ★ 451.9K | 316.4K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $636,600,000.00 | $50,000.00 |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $4.95 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $1.41 | $1.09 |
| 52 Week High | $4.50 | $2.44 |
| Indicator | KLXE | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 36.08 | 62.51 |
| Support Level | $1.49 | $1.37 |
| Resistance Level | $2.57 | $2.30 |
| Average True Range (ATR) | 0.14 | 0.12 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 25.25 | 80.91 |
KLX Energy Services Holdings Inc is a growth-oriented provider of diversified oilfield services to onshore oil and natural gas exploration and production (E&P) companies operating in both conventional and unconventional plays in all of the active basins throughout the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Southwest region.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.